The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma.
Forker L, Gaunt P, Sioletic S, Shenjere P, Potter R, Roberts D, Irlam J, Valentine H, Hughes D, Hughes A, Billingham L, Grimer R, Seddon B, Choudhury A, Robinson M, West CML.
Forker L, et al. Among authors: west cml.
Br J Cancer. 2018 Mar 6;118(5):698-704. doi: 10.1038/bjc.2017.430. Epub 2017 Dec 12.
Br J Cancer. 2018.
PMID: 29235571
Free PMC article.
Clinical Trial.